Additional file 1 of Extrapolating from trials to clinic: a predictive model defining the boundaries of benefit for multiple sclerosis therapies in real-world populations based on systematic review

Additional file 1: Figure S1. PRISMA diagram. Categories of extracted and imputed data elements. Figure S2. Imputation of CEL#. Figure S3. Imputation of CDP confirmed at 12 weeks from CDP confirmed at 24 weeks. Figure S4. Imputation of DD. Penalization function and recalculating efficacies of active comparator trials against “in-silico” placebo arms. Analyses of dynamic data from KM survival curves. Figure S5. Dynamic analysis of treatment effects to develop a more realistic efficacy outcome. Figure S6. I/E criteria predict the baseline age of trial participats. Figure S7. Comparative efficacy of DMTa. Figure S8. Smaller trials have larger residuals from observed versus predicted efficacy. Figure S9. Simple correlation of efficacy predictors with efficacy outcomes. Figure S10. Interactive website for calculating patient-specific risk/benefit predictions.